Shares of Lonza Group Ag (OTCMKTS:LZAGY – Get Free Report) saw unusually-strong trading volume on Wednesday after Royal Bank Of Canada upgraded the stock from a hold rating to a moderate buy rating. Approximately 132,358 shares were traded during trading, an increase of 96% from the previous session’s volume of 67,653 shares.The stock last traded at $65.6850 and had previously closed at $67.15.
Separately, Zacks Research cut shares of Lonza Group from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 4th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Lonza Group currently has a consensus rating of “Hold”.
Check Out Our Latest Stock Analysis on Lonza Group
Lonza Group Trading Up 5.5%
About Lonza Group
Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.
The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.
Read More
- Five stocks we like better than Lonza Group
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- New gold price target
Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.
